Evidence map›Paper›PMID 39934650›Full record

ReviewBMC nephrology2025

New insights in the treatment of DKD: recent advances and future prospects.

Meimei Zhao, Yongtong Cao, Liang Ma

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The Role ofGenes · 2025
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Meimei ZhaoDepartment of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China.
Yongtong CaoDepartment of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China. caoyongtong100@sina.com.
Liang MaDepartment of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China. liangma321@aliyun.com.

Funding

National High Level Hospital Clinical Research Funding 2023-NHLHCRF-DJMS-04the National Natural Science Foundation of China 82074221
6 · The paper itself

Abstract

Diabetic kidney disease (DKD) represents the predominant and severe microvascular complication associated with diabetes, frequently culminating in End-Stage Kidney Disease (ESKD). The escalating prevalence of diabetes has correspondingly led to a rise in DKD incidence, imposing significant challenges on both individuals and society. The etiology of DKD is multifaceted and remains devoid of definitive therapeutic interventions. This article examines the pharmacological actions and mechanisms of different drugs used for the prevention and treatment of DKD that are currently in clinical use or undergoing development. The goal is to offer insights for early intervention based on therapeutic combinations to potentially slow kidney disease progression.

Indexed as

Diabetic NephropathiesHypoglycemic AgentsDisease ProgressionForecastingHumansKidney Failure, ChronicHypoglycemic AgentsAnti-fibrosisAnti-inflammatoryDKDStem cell therapyTherapeutic drug

Identifiers

PMID39934650
PMCPMC11817338

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.